Arbitration Spirals Out of Control in Quest for ADC Dominance
April 21, 2024
Federal Circuit affirms Board decision invalidating Pfizer vaccine patents because claimed molecular weight was a result effective variable derivable by routine optimization.
March 25, 2024
Patent owner improperly dinged by Federal Circuit for correctly following Orange Book listing rules.
December 18, 2023
Increased survival claims survive validity challenge despite one prior art report of successful treatment and ongoing phase III clinical program.
July 08, 2023
Undue experimentation not required to synthesize novel prodrug.
April 17, 2022
Narrow use codes can also lead to failures by generic drug companies to carve-out critical label information.
January 03, 2022
Teva Pharmaceuticals fails to prove that dose reduction for mifepristone when co-administered with a strong CYP3A inhibitor would have been obvious.
December 27, 2021
PTAB rejects Examiner’s argument that crystalline form of an old compound would have been obvious based on obvious to try rationale.
December 05, 2021
PTAB distinguishes Supreme Court’s Myriad decision because salt represents new “chemical construct.”
March 16, 2021
Tablet that “targeted” a PK profile deemed incomprehensible
January 12, 2021
246 Fifth Avenue, Suite 422
New York NY 10001
212.652.0787
246 Fifth Avenue, Suite 422
New York NY 10001
212.652.0787
Subscribe to our blog: